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Abstract
Background: Hepatitis B and C virus infection is a lead cause of morbidity and mortality among hemodialysis
patients. Yet, little research has focused on the morbidity measures of these serious disorders in low and middle
income countries. The study aims to estimate the prevalence of hepatitis B and C among hemodialysis patients in
the West Bank hospitals in Palestine.
Methods: A retrospective medical records review design was performed for all governmental and private hospitals
in the West Bank which provide hemodialysis services for the patients. Data was retrieved from the patients’
medical files and from the computerized health information system in some hemodialysis centers. SPSS software
version 16 was used for data entry and analysis.
Results: In overall, 868 hemodialysis patients attending nine hemodialysis hospitals in the West Bank was recruited.
The overall prevalence of hepatitis B virus was found to be 3.8 % (33 cases) with a range from 0.0 % (in Jericho and
Qalqelia districts) to 11.8 % (in Bethlehem district). Regarding hepatitis C virus, the overall prevalence was estimated
around 7.4 % (64 cases) with a range from 2.9 % (in Nablus district) to 15.9 % (in Qalqelia district).
Conclusions: Although relatively low prevalence of both hepatitis B and C virus was found in a couple of
hemodialysis hospitals, some higher prevalence values urge for the implementation of stricter infection prevention
measures and more effective follow up procedures.
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Background
The primary purpose of the renal system is to maintain
the body’s state of homeostasis by carefully regulating
fluid and electrolytes, removing wastes, and providing
other functions [1]. Dysfunction of the kidneys is com-
mon and may occur at any age and with varying degrees
of severity [2]. Chronic kidney disease (CKD) is an um-
brella term that describes kidney damage or a decrease
in the glomerular filtration rate lasting for three or more
months. CKD is associated with decreased quality of life,
increased health care expenditures, and premature death
[3]. Untreated CKD can result in end-stage kidney dis-
ease (ESKD), which is the final stage of renal failure [4].
ESKD results in retention of uremic waste products and
the need for renal replacement therapies, dialysis, or kid-
ney transplantation [2]. The cause of renal failure may
be a primary kidney disorder or secondary to a systemic
disease or other urologic defects. Hemodialysis is used
for patients who are acutely ill and require short-term
dialysis ranging from days to weeks until kidney resumes
its function as well for patients with advanced CKD and
ESKD who require long-term or permanent renal re-
placement therapy [2].
In hemodialysis, blood is removed from the patient
with needles and plastic tubing and pumped past the
dialysis membrane. Poisons and toxins cross the dialysis
membrane into the dialysate, which is then discarded,
and the blood is returned to the patient [5]. Viral hepa-
titis and human immunodeficiency virus infection are
lead causes of mortality and morbidity in patients with
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hemodialysis (HD). Both are further promoted by the
characteristic immunological dysfunction that develops
in renal failure and interferes with the patient’s ability to
eliminate these viruses. As far as HD is concerned, hepa-
titis B virus (HBV) and hepatitis C virus (HCV) are the
two most important viruses responsible for almost all
the patients’ morbidity [6]. Table 1 below shows some
worldwide prevalence of HBV and HCV among HD
patients [7, 8].
In Gaza strip in Palestine, a study found that the
overall prevalence of HBV and HCV among the HD
patients was 8.1 and 22 %; respectively [7]. However,
no documented data is available regarding the West
Bank. Therefore, this study aims to estimate the
prevalence of HBV and HCV among HD patients in
the West Bank of Palestine in the period from October to
November 2014.
Methods
Study design, settings and population
A retrospective medical records review design was con-
ducted. The study population included all patients who
undergo HD in the West Bank including all governmen-
tal and nongovernmental (An-Najah National University
Teaching Hospital) HD centers at the time of study.
Sample size
A total number of 868 patients were included in the
study during the period from October to November
2014.
Ethical considerations
The study protocol was approved by An-Najah National
University IRB (Institutional Review Board) committee.
Permissions and approval to conduct the study were ob-
tained from the Palestinian Ministry of Health for the
governmental hospitals and from the executive manager
of An-Najah National University Teaching Hospital. The
data was collected from the medical records with per-
missions from the Ministry of Health for governmental
units and the CEO of the private teaching hospital. No
individual names or data are presented in this study.
There was no direct contact with the patients. Data was
retrieved from the patients’ medical files and from the
computerized health information system in some HD
centers.
Data collection
The HD centers included in the study were: Alia hospital
(Hebron), Palestinian medical complex (Ramallah), Beit
Jala hospital (Bethlehem), Dr. Thabit Thabit hospital
(Tulkarm), Dr. Darweesh Nazzal hospital (Qalqelia),
Dr. Khalil Sulaiman hospital (Jenin), Jericho hospital
(Jericho), Al-Shaheed Yaser Arafat hospital (Salfeet)
and An-Najah National University Teaching hospital
(Nablus). The overall number of patients undergoing
HD in each center was recorded and those who have
HBV and HCV in each center were recorded as well.
The patients were included in the study only if they
were attending HD center and undergoing HD on a
regular schedule for more than one month. Patients
who underwent HD for less than one month were
excluded.
Table 1 The worldwide prevalence of HBV and HCV among
hemodialysis patients (The table was adopted from references 7
and 8)
Country Year HBVa HCVb
Total n° of
patients
Percent Total n° of
patients
Percent
Bahrain 2004 81 11.8 NAc NA
Belgian 2000 NA NA 1710 6.8
Brazil 2006 1095 29.8 NA NA
Brazil 2002 NA NA 795 16.5
Brazil 2001 NA NA 428 39
Germany 2002 NA NA 2796 6.1
Germany 1992 NA NA 122 3.3
Greece 2006 49 20.4 NA NA
Greece 2005 NA NA 366 24
India 2005 75 14.2 134 5.9
Indonesia 2002 NA NA 93 63.4
Indonesia 1996 NA NA 76 76.3
Iran 2005 324 4.6 NA NA
Iran 2003 NA NA 838 21.0
Israel 1999 NA NA 65 24.6
Jordan 2008 427 5.9 NA NA
Jordan 2002 NA NA 283 34.6
Kenya 2003 100 8 NA NA
Lebanon 1996 NA NA 317 27.0
Mexico 2004 NA NA 149 6.7
Morocco 2005 186 2 NA NA
Pakistan 2004 97 12.4 NA NA
Saudi Arabia 2001 67 10 NA NA
Spain 2005 86 20.9 NA NA
Switzerland 2000 1713 1.63 NA NA
Syria 1998 NA NA 120 75.0
Tunisia 2001 NA NA 4340 19.1
Turkey 2006 188 25 NA NA
USA 2001 252739 0.9 NA NA
Vietnam! 2013 113 7.0 113 6.0
Co-infection 1 %
a HBV hepatitis B virus, b HCV hepatitis C virus. c NA not applicable!
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Statistical analysis
The data was collected, entered, summarized, tabulated
and analyzed using the Statistical Package for Social
Sciences (SPSS) software version 16 [9]. Descriptive sta-
tistics was performed on the collected data and on each
center separately.
Results
This study focuses on determining the prevalence of
both HBV and HCV among HD patients in the West
Bank.
Patients’ distribution among hemodialysis centers
The study was conducted on 868 HD patients attend-
ing nine HD centers in the West Bank. Table 2 below
shows the distribution of HD patients by center. The
highest number of patients undergoing HD was seen
in both Hebron and Nablus while the lowest was
found in Jericho. As shown in the table, the highest
number of patients with HBV was found in Beit Jala
(11 cases) while for HCV, the highest number was
found in Jenin (18 cases). However, Jericho and Qalqelia
had the lowest (zero) number of HBV. Regarding
HCV, the lowest number of patients was seen in Jericho
(one case).
Prevalence of HBV and HCV by hemodialysis centers
Figure 1 below shows the prevalence of both HBV and
HCV in each HD center in the West Bank. The overall
prevalence of HBV among HD patients in the West
Bank was 3.8 % with a range from 0.0 % in Jericho and
Qalqelia to 11.8 % in Bethlehem. Regarding HCV, the
overall prevalence among HD patients in the West Bank
was 7.4 % with a range from 2.9 % in Nablus to 15.9 %
in Qalqelia (see Fig. 1 below).
Discussion
The highest HBV prevalence in the West Bank was
reported in Beit Jala governmental hospital (11.8 %).
It is unclear why this high prevalence was reported
compared to other West Bank hospitals. However, the
result could be attributed to the fact that the hospital
was established long time ago and that it provides
health care services to different population groups.
Moreover, the hospital has a regional referral Oncology
department that serves the Palestinian population from
South to the Middle of the West Bank and while cancer
patients are immune-compromised, they may contribute
to a higher level of HBV prevalence in this unit. Further-
more, this prevalence was higher compared to some other
countries like USA, Morocco, Iran, but lower than other
countries like Pakistan, Spain, Brazil, Turkey and Vietnam
(Table 1) [7, 8].
On the other hand, the prevalence of HCV was
2.87 % at An-Najah National University Teaching
Hospital in Nablus which was the lowest prevalence
of HCV among hemodialysis centers in the West
Bank. This prevalence was lower than other countries
such as Belgian, Germany, India and Vietnam [7, 8].
This could be explained by that this hospital is a
teaching hospital which was recently established and
provides well and advanced tertiary services. There-
fore, emphasis and attention on preventive measures
compared to other hospitals might be more signifi-
cant in this hospital. However, the prevalence of HCV
was 15.90 and 15.38 % in Qalqelia and Jenin districts,
respectively. These were the highest prevalences of
HCV reported in the West Bank. Indeed, this high
prevalence of HCV needs more investigations in order
to better understand why the prevalence of HD pa-
tients with HCV is so high in these governmental
hospitals. However, higher prevalence levels were reported
in other countries worldwide such as Greece, Israel,
Indonesia, Syria, Tunisia and Lebanon (Table 1).
In Arab countries, the prevalence of chronic HBV
among HD patients ranged from 2.0 % in Morocco to
11.8 % in Bahrain [10–12]. Moreover, the prevalence of
HCV antibodies among HD patients has been reported
to range from 27 % in Lebanon to 48.9 % in Syria [13].
In Jordan, the prevalence of HBV in seven hospitals of
the Royal Medical Services was found to be 5.9 % out of
the 427 studied subjects [12]. In Casablanca, Morocco a
high HCV prevalence (76 %; N = 186) was reported com-
pared to relatively small HBV prevalence (2 %; N = 186)
among chronic hemodialysis patients in the university
hospital [11]. In Egypt however, a cross-sectional
study was conducted on 2977 individuals. The study
determined the prevalence of anti-HCV and HBV sur-
face antigen seropositivity in Damietta Governorate,
Egypt. Only 1.1 % were infected with HBV and 9.3 %
Table 2 Patients distributions and numbers with HBV and HCV
by hemodialysis centers in the West Bank
Hemodialysis center N° of patients n° with HBVa n° with HCV a
Hebron 177 9 13
Ramallah 135 4 5
Nablus 174 2 5
Beit Jala 93 11 8
Tulkarm 71 2 4
Qalqelia 44 0 7
Jenin 117 4 18
Jericho 25 0 1
Salfeet 32 1 3
Total 868 33 64
aHBV hepatitis B virus, HCV hepatitis C virus
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with HCV [14]. Regarding other parts of the world,
in India for example, the prevalence of HBV and
HCV were found to be 5.5 and 10.9 %, respectively
after starting the HD [15]. Moreover, in spite of the
reduction in HBV spread within dialysis centers (for
example in our study, the prevalence of HBV in
Jericho and Qalqelia governmental units was found to
be zero in both districts), some isolated outbreaks of
HBV infection continue to be reported among HD
patients in developed countries [16].
This study has some limitations. It does not differ-
entiate between patients who developed the hepatitis
infection before or after starting the hemodialysis
process, therefore, it does not investigate the risk fac-
tors of developing HBV and HCV. This would have
provided an insight to understand the preventive
measures in each hospital. However, this descriptive
study could be used as a baseline for future hypoth-
esis generating analytical studies. Furthermore, no
other variables were taken into consideration when
estimating the prevalence of HBV and HCV among
hemodialysis patients such as gender, age, place of
residence or other socio-demographic factors. Never-
theless, the study provides a general overview of this
health event and urges further future investigations in
low and middle income countries to shed the light to
this life threatening disorders.
Recommendations
Further studies should be conducted to evaluate the risk
factors of both HBV and HCV among patients undergo-
ing hemodialysis in the West Bank hospitals. These
include follow up studies to investigate whether the
infection was established before or after starting the
hemodialysis to form a more comprehensive opinion on
why prevalence values are higher in some Palestinian
hospitals compared to other national hospitals. Develop-
ing effective strategies to prevent the occurrence of HBV
and HCV infections among HD patients is also essential.
Investigation of the prevalence and risk factors of both
HBV and HCV among hemodialysis patients in the East
Jerusalem hospitals is recommended.
Conclusions
Although relatively low prevalence of both hepatitis B
and C viruses was found in a couple of hemodialysis
hospitals, some higher prevalence values urge for effect-
ive prevention control measures and more strict follow
up procedures.
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Fig. 1 Prevalence of HBV and HCV by hemodialysis center in the West Bank. HBV: Hepatitis B virus; HCV: Hepatitis C virus
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